Marshall Biomedical Sciences Graduate Program is well represented at Experimental Biology Meeting

Allison, Miranda, Kristeena

BMS Ph.D. students, Allison, Miranda, and Kristeena, take a time out from research to enjoy a Boston Red Sox game!

Marshall University’s Biomedical Sciences (BMS) Graduate Program was well represented at the Experimental Biology Meeting that recently took place in Boston, MA. The annual national meeting involves over 14,000 scientists and exhibitors representing fields of study ranging from anatomy, physiology, pathology, and biochemistry to epigenetics, nutrition, cancer biology, and pharmacology. Some Marshall School of Medicine faculty and students were invited to give oral presentations of their research, while others were able to present their research during the poster sessions. The list of attendees is given below.

Oral presentations by:

Piyali Dasgupta, Ph.D.

Piyali Dasgupta, Ph.D. -
Invited speaker for special session “Molecular Biology of Lung Malignancy” – Title: “Nicotine increases the expression of alpha7-nicotinic receptors (alpha7-nAChRs) in human squamous cell lung cancer cells via Sp1/GATA pathway”

 

 

W. Elaine Hardman, Ph.D.W. Elaine Hardman, Ph.D. – Invited speaker for special session “What Comes First: The Food or the Nutrient?” – Title: “Whole foods or their bioactive components? Potential of walnuts in cancer prevention and treatment.” 

 

 

Maria Serrat, Ph.D.

Maria Serrat, Ph.D. – Invited speaker for special session “Bone Physiology under Environmental Stress” – Title: “Temperature effects on the growth plate and its vasculature”

 

 

 

Allison Wolf, Ph.D. CandidateM. Allison Wolf, BMS Ph.D. Candidate – Invited speaker for special session – Title: “Benzyl isothiocyanate enhances chemosensitivity and inhibits migration and invasion of head and neck squamous cell carcinoma”

 

 

 

 

Katie_Brown_EB

Katie Brown, M.S. – Invited speaker for special session “Molecular Biology of Lung Malignancy” – Title: “Inhibition of cholinergic signaling causes apoptosis in human bronchioalveloar carcinoma”

 

 

Ron, Miranda, Allison, Johannes, Kristeena_EB

Poster presentations by:
Miranda Carper, BMS Ph.D. Candidate
Johannes Fahrmann, BMS Ph.D. Candidate Christopher McNees, MU student 
Rounake Nande, BMS Ph.D. Student
Chris Racine, BMS Ph.D. Student
Kristeena Ray, BMS Ph.D. Student
Cody Stover, MU student
Brent Thornhill, MU graduate
Monica Valentovic, Ph.D., Toxicology and Environmental Health Sciences’ Research Cluster Coordinator
Gary Rankin, Ph.D., Toxicology and Environmental Health Sciences’ 
Research Cluster

Dr. Maria Serrat, Assistant Professor in the Department of Anatomy and Pathology and researcher within the Neuroscience and Developmental Biology Research Cluster, had the opportunity to give an oral presentation as well as participate in a focus group that evaluated anatomy education material for a publisher. 

Johannes at Poster

Serrat said she was happy to see Marshall well represented at the meeting and that “the large number of Marshall attendees says a lot about the expanding research emphasis of our institution.”

Kristeena at Poster

Carper at Poster

 

 

Study focuses on potential lung cancer therapies

HUNTINGTON, W.Va. – Scientists from Marshall University, Piyali Dasgupta, Ph.D.along with colleagues at Alderson-Broaddus College in Philippi, have completed a study that may eventually help lead to the development of new treatments for lung cancer.

Their results were published in the Feb. 15 issue of Cancer Research, the most frequently cited cancer journal in the world.

At Marshall, Dr. Piyali Dasgupta, associate professor in the Department of Pharmacology, Physiology and Toxicology in the Joan C. Edwards School of Medicine, worked on the study with her research team of Jamie Lau, Kathleen Brown and Brent Thornhill, and undergraduate students Cody Stover and Christopher McNees.

Researchers in Dasgupta’s lab explore how the various components of tobacco, especially nicotine, advance the progression of lung cancer.                                       

Dasgupta said this study focused on a specific type of lung cancer called bronchioalveolar carcinomas, or BACs, which are known to be associated with smoking. She and the other scientists working on the project looked at the cellular pathways through which nicotine—the addictive component in cigarettes—promotes the growth and survival of BACs. 

According to Dasgupta, nicotine itself is not a carcinogen, but studies have shown it can induce the growth and metastasis of lung cancers. It can also protect lung cancer cells against the beneficial effects of chemotherapy.

She said, “In this study, we found that nicotine raised the levels of specific neurotransmitters, or ‘chemical messengers,’ in human BACs. When we used a drug, vesamicol, to interrupt the neurotransmitters’ pathways, the nicotine-induced growth of these carcinomas was significantly suppressed. Our findings are important because they indicate that agents like vesamicol may be useful in the treatment of human lung cancers.” 

More information about the research is available online at http://cancerres.aacrjournals.org/content/73/4/1328.abstract?sid=c29c4530-21a3-4652-a977-23b25019258a.

The study was funded in part by a Young Clinical Scientist Award from the Flight Attendant Medical Research Institute.

For more information, contact Dasgupta at dasgupta@marshall.edu or 304-696-3612.

###

Marshall scientist awarded NIH grant for lung cancer research

The following story from the Marshall University Research Corporation highlights two researchers within the Biomedical Sciences Graduate Program: Piyali Dasgupta, Ph.D., and Monica Valentovic, Ph.D.


Piyali Dagupta, Ph.D., and Monica Valentovic, Ph.D.

 HUNTINGTON, W.Va. – A Marshall University faculty member has been awarded a three-year, $426,000 grant by the National Institutes of Health (NIH) to further her lung cancer research.

Dr. Piyali Dasgupta, associate professor in the Department of Pharmacology, Physiology and Toxicology in the university’s Joan C. Edwards School of Medicine, will use the grant to continue her work to determine if the nutritional agent capsaicin—the active ingredient in chili peppers—can improve the anti-cancer activity of the commonly used chemotherapy drug cisplatin in patients with small cell lung cancer.

Dasgupta received the funding through the National Cancer Institute’s Academic Research Enhancement Award program. The program supports research projects in the biomedical and behavioral sciences that strengthen the research environment of the institution and expose students to research. Her co-investigator is Dr. Monica Valentovic, a professor in the same department.

“Small cell lung cancer is characterized by a high rate of growth, early metastasis and a dismal survival rate,” said Dasgupta. “Although chemotherapy works well initially in these patients, they often relapse quickly and become unresponsive to chemotherapy. Since the preliminary data in our laboratory shows that capsaicin manifests anti-cancer activity in this type of cancer, we are hopeful our studies under this new grant may lead to new treatments.”

She continued, “I am thrilled to receive this funding and I am grateful to a lot of people who have been instrumental in our success to this point. My collaborator Dr. Valentovic is a fabulous scientist to work with. I am also grateful to all the members of my lab for their hard work and dedication.”

Dasgupta also acknowledged the support of the chairman of her department, Dr. Gary Rankin, and acknowledged Dr. Marcia Harrison and the MU-ADVANCE program, which she says made it possible for undergraduate students to work in her lab. MU-ADVANCE is a National Science Foundation-funded program to help increase the number of female science and engineering faculty at the university.

Dasgupta says she believes her proposal was selected for funding at least in part because the grant program’s focus on student research made it a good match for her lab. Undergraduates working in her lab have a track record of receiving research grants, authoring publications and presenting their findings at international conferences.

Dr. John M. Maher, Marshall’s vice president for research, congratulated the researchers, saying, “NIH grants are extraordinarily competitive, and I applaud Drs. Dasgupta and Valentovic for having a successful application. They are doing vital research that may very well have a positive impact on human health in the not-so-distant future. In addition, the grant will allow them to continue to give students hands-on, meaningful research opportunities in the lab.”

In addition to receiving the new NIH funding, Dasgupta recently was notified that her grant from the Flight Attendant Medical Research Institute has been renewed for an additional two years. The renewal, which extends the original three-year award, makes the total grant worth nearly $550,000. That grant is funding Dasgupta’s study of how nicotine, the active component in cigarette smoke, facilitates the progression of lung cancer. Valentovic is also the co-investigator on that award.


Contact:  Ginny Painter, Communications Director, Marshall University Research Corporation, 304.746.1964

Dr. Piyali Dasgupta presents at the 2011 Experimental Biology Conference

Piyali Dasgupta, Ph.D.Dr. Piyali Dasgupta, Assistant Professor in the Department of Pharmacol­ogy, Physiology, and Toxicology, presented “Long-term exposure to nico­tine upregulates the expression of α7-nicotinic receptors by autoregulatory mechanisms in human squamous cell lung carcinoma,” at the Experimen­tal Biology conference, held April 9-13, 2011, in Washington, D.C. Four members of her laboratory also presented, including Mr. Brandon Shiflett, who was selected to present “MG624, an α7-nicotinic receptor antagonist suppresses the growth of human SCLC“ at a special session to highlight graduate student research in Pathology. Dr. Dasgupta was named “Outstanding Graduate Faculty Advisor of 2011” at the Joan C. Edwards School of Medicine. Her research examines the effects of nicotine (the active component of cigarettes) in regulating cellular responses, such as programmed cell death and cell growth, in the context of lung cancer. 

Dr. Piyali Dasgupta to chair a special session at Experimental Biology 2012

Piyali Dasgupta, Ph.D.Dr. Piyali Dasgupta has been invited to chair a special session at the Experimental Biology 2012 conference in San Diego. The minisymposium that she will be leading is entitled “Modeling Cancer: Biological and Therapeutic Implications.”

The invitation to chair the special session came from the Director of the Division of Experimental Pathology for the American Society for Investigative Pathology (ASIP). Dr. Dasgupta is a member of the ASIP and has regularly presented at Experimental Biology over the past few years, including several oral seminar presentations. Experimental Biology is an annual meeting that draws almost 14,000 scientists and exhibitors. Scientists attending represent universities, academic institutions, government agencies, private corporations, and non-profit organizations. Participating societies include the ASIP, the American Association of Anatomists (AAA), the American Physiological Society (APS), the American Society for Biochemistry and Molecular Biology (ASBMB), and others.Dr. Dasgupta is Assistant Professor in the Department of Pharmacol­ogy, Physiology, and Toxicology. She was named “Outstanding Graduate Faculty Advisor of 2011” at the Joan C. Edwards School of Medicine. Her research examines the effects of nicotine (the active component of cigarettes) in regulating cellular responses, such as programmed cell death and cell growth, in the context of lung cancer.

Being asked to chair a session at such a prestigious conference is quite an honor. Congratulations, Dr. Dasgupta!

Clayton Crabtree receives grant from Sigma Xi to study diabetic retinopathy

Clayton CrabtreeA Marshall University biology student has been awarded a grant to conduct research on diabetic retinopathy, a common eye disease during which excessive growth of blood vessels causes damage to the retina.

Clay M. Crabtree, a senior from Kenova, will receive the $1,800 Grants-in-Aid of Research award from the national science society Sigma Xi. The award will help fund his project to test potential treatments for the disease, which is the leading cause of blindness among working-age Americans.

According to Crabtree, cigarette smoking is a risk factor for diabetic retinopathy because nicotine promotes the growth of blood vessels.

“Agents that can block the actions of nicotine should be useful for the treatment of diabetic retinopathy,” he continued. “My research involves testing three of these compounds for their ability to block the growth of new vessels in the retina.”

Crabtree’s mentor, Dr. Piyali Dasgupta of Marshall’s Department of Pharmacology, Physiology and Toxicology, said the grant will give Crabtree the opportunity to further his education through hands-on experience conducting research that could have a real impact on the health of people across the region.

“The findings from Clay’s project will be highly relevant to West Virginia because our state has a large number of diabetic patients who are active smokers,” she added. “It is a very commendable achievement to receive one of these grants and I look forward to seeing his project progress.”

Sigma Xi promotes the scientific enterprise and honors scientific achievement. The organization’s Grants-in-Aid of Research program, with funds designated from the National Academy of Sciences, provides undergraduate and graduate students with up to $2,500 for vision-related research.

Students use the funding to pay for travel expenses to and from a research site, or for purchase of laboratory equipment necessary to complete their research project.

According to Sigma Xi, the Grants-in-Aid of Research program is highly competitive and only approximately 20 percent of applicants receive funding.

For more information, contact Dasgupta at (304) 696-3612.

BMS Graduate Student Brandon Shiflett invited to special session by ASIP

Brandon ShiflettBiomedical Sciences Graduate Student Brandon Shiflett has been selected for a special honor by the American Society for Investigative Pathology (ASIP). Brandon is only one of eighteen students who have been chosen to present their research projects at a special session of the ASIP Annual Meeting at Experimental Biology 2011 in Washington, DC. The session is entitled “Highlights: Graduate Student Research in Pathology.” According to the ASIP, it is considered an honor to be invited to this special session. More about the ASIP, its annual meeting, and this special session can be found on the ASIP website.

Brandon’s abstract is entitled “MG624, an α-7nicotinic receptor antagonist suppresses the growth of human SCLC.” SCLC, or Small Cell Lung Cancer, is a rapidly-progressing disease that metastasizes early and has very low survival rates. Interestingly, nearly 90% of all reported SCLC cases have been correlated to smoking, which suggests that nicotine and other tobacco components may contribute to the disease’s pathophysiology. The data Brandon will present shows that long-term nicotine exposure stimulates the growth of human SCLCs. Nicotine stimulates nicotinic acetylcholine receptors (nAChRs), causing these cells to proliferate. By isolating and disabling a specific subunit of a nicotinic acetylcholine receptor, α7-nAChR, Brandon and others on his project were able to suppress nicotine’s stimulatory effects. This indicates that the α7-nAChR subtype is important in the proliferation of human SCLCs, and that antagonizing it could be a possible treatment for the condition. One such antagonist, called MG624, was shown in Brandon’s study to not only induce apoptosis, or cell death, in human SCLC cells, but also suppress the nicotine-induced growth of these cells. The data from his study suggests that MG624 may have potential for treating human SCLCs.

Brandon Shiflett works in the laboratory of Dr. Piyali Dasgupta at the Marshall University Joan C. Edwards School of Medicine. He is currently completing his second year as a Medical Sciences student in the M.S. in Biomedical Sciences Program at Marshall. He will join the medical school in the fall as a first-year student.

Congratulations to Brandon Shiflett, Dr. Dasgupta, and all others who participated in this project!